Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 7/20 | 0.45 |
| ▸ | FDPS | P14324 | 11/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2602387 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL7992702 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL10384653 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL10386392 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL8771494 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL24793822 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL10385222 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL10384529 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL10385170 | 0.98 | GGPS1 (0.46) | GGPS1FDPSSMPD1LPAR1LPAR3 | |
| SCHEMBL20388294 | 0.93 | FDPS (0.39) | GGPS1FDPSSMPD1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | GGPS1 1889/4885FDPS 1865/4885SMPD1 4303/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | GGPS1 1889/4885FDPS 1865/4885SMPD1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.